Category: Uncategorized
Alyssa Frechette, a continuous improvement manager who has achieved several promotions and several lateral moves over the last seven years, shares insights on how she has achieved such rapid early career success in STEM.
Explore how to boost voting turnout and civic participation among STEM students in this episode of Diverse: a SWE podcast!
SWENext Influencer Zeynep S. shares the activities, guest speakers, and competitions planned for her SWENext Club this year.
SWE member Lori McDowell reflects on the mindset shifts that helped her bounce back and thrive after a difficult situation in her STEM career.
The SWE Annual Conference & Career Fair is a place where women, nonbinary individuals, and men as allies of all backgrounds can support the overall persistence and success for the engineering and technology profession of those underrepresented in the field. Those who think otherwise should reconsider attending.
As part of their spotlight month, the Latinos AG has compiled a list of Latina engineers who are breaking barriers in the STEM field.
Learn about Pfizer’s Rotational Programs and Early Talent Opportunities through the stories of a Pfizer Digital colleague who recently completed one of these programs.
Upon a persistent request from the Terra community, Kwon went against his initial plan and publicly shared a burn address for LUNA on May 21. 839 Total views 4 Total shares The recent Terra revival plan announced by Do Kwon, the co-founder and CEO of Terraform Labs, received mixed reactions as many questioned the effectiveness […]
The Ethereum ecosystem still has far more developers than rival networks, but they are catching up with a faster rate of growth. Ethereum competitors such as Polkadot, Solana, and Binance Smart Chain are growing faster in terms of development activity according to crypto research firm Electric Capital which released its findings on the blockchain development […]
Shares of Pfizer Inc. PFE, +2.02% rallied 2.5% in afternoon trading Wednesday, after BofA Securities analyst Geoff Meacham turned bullish on the drug maker, saying its COVID-19 pill Paxlovid could alleviate concerns over a “cluster of patent expirations” starting in 2025. Meacham raised his rating to buy, after being at neutral since he started covering […]
